Page last updated: 2024-09-03

n-hydroxysuccinimidyl digoxigenin-3-o-methylcarbonyl-epsilon-aminocaproate and Lymphoma, Non-Hodgkin

n-hydroxysuccinimidyl digoxigenin-3-o-methylcarbonyl-epsilon-aminocaproate has been researched along with Lymphoma, Non-Hodgkin in 1 studies

*Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. [MeSH]

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Hazuku, T; Kawano, K; Kodama, Y; Maruyama, R; Miyazaki, Y; Ohtsuka, E; Saburi, M; Sakata, M; Takata, H; Urabe, S; Wada, J1

Other Studies

1 other study(ies) available for n-hydroxysuccinimidyl digoxigenin-3-o-methylcarbonyl-epsilon-aminocaproate and Lymphoma, Non-Hodgkin

ArticleYear
[Busulfan/thiotepa followed by autologous peripheral blood stem cell transplantation for refractory diffuse large B-cell lymphoma accompanied by hypopyon].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2022, Volume: 63, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Doxorubicin; Humans; Lymphadenopathy; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Rituximab; Thiotepa; Transplantation, Autologous; Vincristine

2022